Ecstasy (MDMA) alters cardiac gene expression and DNA methylation: Implications for circadian rhythm dysfunction in the heart

Toxicological Sciences

Volumn 148, Issue 1, 2015, Pages 183-191

  Koczor, Christopher A ^a   Ludlow, Ivan ^a   Hight, Robert S ^a   Jiao, Zhe ^a   Fields, Earl ^a   Ludaway, Tomika ^a   Russ, Rodney ^a   Torres, Rebecca A ^a   Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Circadian rhythm heart; DNA methylation; Ecstasy; MDMA; Microarray

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CIRCADIAN RHYTHM SIGNALING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; NPAS2 PROTEIN; PER3 PROTEIN; PYRIMIDINE NUCLEOTIDE; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; CARDIOTOXIN; MIDOMAFETAMINE; PSYCHEDELIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ECHOCARDIOGRAPHY; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; HEART FUNCTION; HEART MUSCLE CELL; HEART WEIGHT; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROMOTER REGION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMYOPATHY; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEART; HEART ARRHYTHMIA; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL ANALYSIS; TACHYCARDIA;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CARDIOTOXINS; CIRCADIAN RHYTHM SIGNALING PEPTIDES AND PROTEINS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HALLUCINOGENS; HEART; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MYOCARDIUM; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SURVIVAL ANALYSIS; TACHYCARDIA;

EID: 84947705372     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv170     Document Type: Article

References (31)

1. Ahmad, F., Seidman, J. G., and Seidman, C. E. (2005). The genetic basis for cardiac remodeling. Annu Rev Genomics Hum. Genet. 6, 185-216.
2. Battaglia, G., Brooks, B. P., Kulsakdinun, C., and De Souza, E. B. (1988). Pharmacologic profile of MDMA (3, 4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 149, 159-163.
3. Bexis, S., and Docherty, J. R. (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Br. J. Pharmacol. 147, 926-934.
4. Colado, M. I., Camarero, J., Mechan, A. O., Sanchez, V., Esteban, B., Elliott, J. M., and Green, A. R. (2001). A study of the mechanisms involved in the neurotoxic action of 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br. J. Pharmacol. 134, 1711-123.
5. Colbron, S., Jones, M., and Biello, S. M. (2002). MDMA alters the response of the circadian clock to a photic and non-photic stimulus. Brain Res. 956, 45-52.
6. Dafters, R. I., and Biello, S. M. (2003). The effect of 3, 4-methylenedioxymethamphetamine ('Ecstasy') on serotonergic regulation of the mammalian circadian clock mechanism in rats: the role of dopamine and hyperthermia. Neurosci. Lett. 350, 117-121.
7. de la Torre, R., Farre, M., Roset, P. N., Lopez, C. H., Mas, M., Ortuno, J., Menoyo, E., Pizarro, N., Segura, J., and Cami, J. (2000). Pharmacology of MDMA in humans. Ann. N. Y. Acad. Sci. 914, 225-237.
8. DeBruyne, J. P., Weaver, D. R., and Reppert, S. M. (2007). CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat. Neurosci. 10, 543-545.
9. Finnegan, K. T., Ricaurte, G. A., Ritchie, L. D., Irwin, I., Peroutka, S. J., and Langston, J. W. (1988). Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res. 447, 141-144.
10. Freese, T. E., Miotto, K., and Reback, C. J. (2002). The effects and consequences of selected club drugs. J. Subst. Abuse Treat. 23, 151-156.
11. Green, A. R., Cross, A. J., and Goodwin, G. M. (1995). Review of the pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology (Berl) 119, 247-260.
12. Greene, S. L., Dargan, P. I., O'Connor, N., Jones, A. L., and Kerins, M. (2003). Multiple toxicity from 3, 4-methylenedioxymethamphetamine ('ecstasy'). Am. J. Emerg. Med. 21, 121-124.
13. Gudelsky, G. A., and Nash, J. F. (1996). Carrier-mediated release of serotonin by 3, 4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66, 243-249.
14. Henry, J. A., Jeffreys, K. J., and Dawling, S. (1992). Toxicity and deaths from 3, 4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340, 384-387.
15. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
16. Johnson, E. A., Sharp, D. S., and Miller, D. B. (2000). Restraint as a stressor in mice: against the dopaminergic neurotoxicity of D-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection. Brain Res. 875, 107-118.
17. Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2013). Monitoring the Future national results on drug use: 2012 Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, The University of Michigan.
18. Kalant, H. (2001). The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can. Med. Assoc. J. 165, 917-928.
19. Koczor, C. A., Lee, E. K., Torres, R. A., Boyd, A., Vega, J. D., Uppal, K., Yuan, F., Fields, E. J., Samarel, A. M., and Lewis, W. (2013). Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis. Physiol. Genomics 45, 597-605.
20. Lenton, S., Boys, A., and Norcross, K. (1997). Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction 92, 1327-1337.
21. McCann, U. D., Szabo, Z., Seckin, E., Rosenblatt, P., Mathews, W. B., Ravert, H. T., Dannals, R. F., and Ricaurte, G. A. (2005). Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30, 1741-1750.
22. Mizia-Stec, K., Gasior, Z., Wojnicz, R., Haberka, M., Mielczarek, M., Wierzbicki, A., Pstras, K., and Hartleb, M. (2008). Severe dilated cardiomyopathy as a consequence of Ecstasy intake. Cardiovasc. Pathol. 17, 250-253.
23. Neubauer, S. (2007). The failing heart-an engine out of fuel. N. Engl. J. Med. 356, 1140-1151.
24. O'Shea, E., Esteban, B., Camarero, J., Green, A. R., and Colado, M. I. (2001). Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40, 65-74.
25. Peroutka, S. J., Newman, H., and Harris, H. (1988). Subjective effects of 3, 4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1, 273-277.
26. Rattray, M. (1991). Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 26, 77-87.
27. Rudnick, G., and Wall, S. C. (1992). The molecular mechanism of "ecstasy" [3, 4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U. S. A. 89, 1817-1821.
28. Shenouda, S. K., Lord, K. C., McIlwain, E., Lucchesi, P. A., andVarner, K. J. (2008). Ecstasy produces left ventricular dysfunction and oxidative stress in rats. Cardiovasc. Res. 79, 662-670.
29. Shenouda, S. K., Varner, K. J., Carvalho, F., and Lucchesi, P. A. (2009). Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. Cardiovasc. Toxicol. 9, 30-38.
30. Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856 Findings). Rockville, MD.
31. Vitaterna, M. H., King, D. P., Chang, A. M., Kornhauser, J. M., Lowrey, P. L., McDonald, J. D., Dove, W. F., Pinto, L. H., Turek, F. W., and Takahashi, J. S. (1994). Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 264, 719-725.